Metformin reduces hirsutism acne in PCOS.(Clinical Insights)(polycystic ovary syndrome )(Author Abstract)
Contemporary OB/GYN, August, 2003
The first investigation of its kind to specifically address metformin’s effects on cosmetic problems has found that the drug significantly improves acne and hirsutism in women with polycystic ovary syndrome (PCOS). The results of the small study were reported by Turkish investigators at The Endocrine Society’s Annual Meeting.
The 12-month study enrolled 20 women with PCOS who had hirsutism and acne, as assessed by the Ferriman and Gallwey (F-G) score and patient self-assessment, and lesion counts, respectively. Treatment consisted of 850 mg of mefformin twice daily and response was gauged at baseline and after 4, 8, and 12 months.
At the end of the study period, there was a significant improvement in hirsutism scores (F-G score 19.9 vs. 16.3; P<0.01) and patient self-assessment (5.4 vs. 3.8; P<0.01). Inflammatory lesions were reduced by 50.6%, noninflammatory lesions by 40.6%, and acne severity was reduced by 42.4%. Improvements in hirsutism and acne were significantly correlated with improvements in insulin sensitivity. Treatment-related adverse events, most of which were mild, were experienced by 4.3% of the women. Dereli D, et al. The effect of metformin on hirsutism and acne in polycystic ovary syndrome. Poster presented at: Endo 2003. The Endocrine Society's 85th Annual Meeting; Friday, June 20, 2003; Philadelphia, Pa. Poster P2-176. COPYRIGHT 2003 A Thomson Healthcare Company COPYRIGHT 2003 Gale Group